100 项与 Manifold Health Tech Usa, Inc. 相关的临床结果
0 项与 Manifold Health Tech Usa, Inc. 相关的专利（医药）
Plus, news about Manifold and Phenomix:
Candel Therapeutics’ viral immunotherapy impresses in pancreatic cancer:
In a small Phase 2 trial for patients with borderline resectable pancreatic cancer, those who received Candel’s experimental therapy
had
28.8 months of estimated overall survival time compared to the 12.5 months in those who received standard chemo. Four of seven patients who received CAN-2409 were still alive at the March 29 data cut-off, with two patients surviving more than four years from enrollment. Only one out of six patients who received chemotherapy was still alive. Candel’s stock
$CADL
rose nearly 40% on Thursday morning.
— Lei Lei Wu
100 项与 Manifold Health Tech Usa, Inc. 相关的药物交易
100 项与 Manifold Health Tech Usa, Inc. 相关的转化医学
